Adjuvant pharmacological modulation with Cytoflavin in rehabilitation at stages 2—3 in patients with acute cerebral insufficiency and post-intensive care syndrome

To further evaluate the efficacy of Cytoflavin (Inosine+Nicotinamide+Riboflavin+Succinic Acid) in post-intensive care syndrome (PICS) in patients who have suffered ischemic stroke and to present the design of a new prospective study on the rehabilitation of PIC syndrome in patients with acute cerebral insufficiency (ACI). A repeated analysis of 53 patients who had suffered ischemic stroke was conducted, who were divided into 2 groups. In addition to a complex of neurorehabilitation measures, including velokinetic training and a verticalization program, the treatment regimen for patients in group 1 (n=36) was supplemented with Cytoflavin, a solution for intravenous administration, for 10 days. Patients in group 2 (n=17) underwent a similar rehabilitation complex for 10 days, but without the addition of Cytoflavin. The use of Cytoflavin in patients with ischemic stroke may be useful for early rehabilitation of patients with PICS. In the examined patients, Cytoflavin during rehabilitation treatment in the early recovery period did not have a direct effect on reducing the time for normalization of the gravitational gradient, but, in general, increased the degree of activity recovery (Barthel index). A new prospective randomized controlled trial will include 90 adult patients with signs of PICS who were in the intensive care unit for at least 3 days due to acute cerebral insufficiency, hospitalized for stages 2—3 of rehabilitation in the period from 14 to 60 days after the onset of the disease. The group of patients who received Cytoflavin at stage 1 during the RehabICU program will be assigned to the Basic Therapy+Cytoflavin group. The comparison group will receive the same set of rehabilitation measures, with the exception of Cytoflavin. The study is scheduled to be conducted from May 2024 to October 2025. The results of the planned prospective study will clarify the feasibility of including Cytoflavin in clinical recommendations for the treatment of PICS at the stages of rehabilitation treatment.